Tocilizumab (RoActemra) poST Marketing Observational Study in DMARD-IR Patients to Assess Efficacy and Safety in routiNE Clinical Practice - STONE

Trial Profile

Tocilizumab (RoActemra) poST Marketing Observational Study in DMARD-IR Patients to Assess Efficacy and Safety in routiNE Clinical Practice - STONE

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms STONE
  • Sponsors Roche
  • Most Recent Events

    • 26 Jan 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 12 Jan 2015 Status changed from discontinued to recruiting as reported by ClinicalTrials.gov record.
    • 23 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top